Neurocrine Biosciences, Inc.
Industry
- Biotechnology
- Pharmaceuticals
Other Names/Subsidiaries
- Diurnal Group PLC
Latest on Neurocrine Biosciences, Inc.
Michael Davis, the Center for Drug Evaluation and Research’s new deputy director, brings experience leading US Food and Drug Administration reviews and psychedelic drug development. CDER Acting Direct
Welsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in
Neurocrine Biosciences’ NBI-1117568 has shown significant improvement in symptoms and overall severity in adults with schizophrenia in new data presented from a Phase II dose-finding study, and the co
Industry leaders attending the Bank of America Global Healthcare Conference 13-14 May were pressed for early reaction to President Donald Trump’s executive order on US drug pricing, but with the confe